Prostate cancer: Screening and early detection

Cancer Control

Volumn 8, Issue 2, 2001, Pages 133-140

  Cookson, Michael S ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER SCREENING; CANCER STATISTICS; COST; HUMAN; METASTASIS; PRACTICE GUIDELINE; PROSTATE CANCER;

EID: 0035048729     PISSN: 10732748     EISSN: None     Source Type: Journal    
DOI: 10.1177/107327480100800203     Document Type: Article

References (41)

1. Issues in prostate cancer screening
2. Cancer statistics, 1998
3. An adjustment to the 1997 estimate for new prostate cancer cases
4. The epidemiology of prostate cancer part I: Descriptive epidemiology
5. The epidemiology of prostate cancer part II: The risk factors
6. Early age at diagnosis in families providing evidence of linkage to the hereditary prostate cancer locus (HPC1) on chromosome 1
7. Prostate specific antigen: A decade of discovery: What we have learned and where we are going
8. Effect of finasteride on prostate-specific antigen density
9. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination: Enhancement of specificity with free PSA measurements
10. Prostate Cancer Awareness Week: September 22 to 28, 1997
11. Risks and complications of transrectal ultrasound guided prostate needle biopsy: A prospective study and review of the literature
12. Clinical significance of repeat sextant biopsies in prostate cancer patients
13. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate
14. The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: Results of a prospective clinical trial
15. Serum prostate-specific antigen in a community-based population of healthy men: Establishment of age-specific reference ranges
16. Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: Receiver operating characteristic curves
17. Age-specific reference ranges for prostate-specific antigen in black men
18. Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men
19. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease
20. Prostate specific antigen density: A means for distinguishing benign prostatic hypertrophy and prostate cancer
21. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial
22. Statistical considerations in cancer screening programs
23. Economics of screening for carcinoma of the prostate
24. Population-based prostate cancer trends in the United States: Patterns of change in the era of prostate-specific antigen
25. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of a multicenter clinical trial of 6,630 men
26. Screening for prostate cancer: An analysis of the early experience
27. Prognostic significance of prostate-specific antigen in stage T1c prostate cancer treated by radical prostatectomy
28. Implications of stage-specific survival rates in assessing recent declines in prostate cancer mortality rates
29. Downward trend in prostate cancer mortality in Quebec and Canada
30. Screening decreases prostate cancer death: First analysis of the 1998 Quebec prospective randomized controlled trial
31. Decrease in prostate cancer mortality following the introduction of prostate specific antigen (PSA) screening in the Federal State of Tyrol, Austria
32. The European randomized study of screening for prostate cancer: An update
33. Prostate cancer screening trials: Fending off critics to recruit men
34. Screening for prostate cancer. American College of Physicians
35. Prostate cancer screening update: Should new developments change our practice?
36. Longitudinal screening for prostate cancer with prostate-specific antigen
37. Longitudinal follow-up for Prostate Cancer Awareness Week (PCAW): Screening intervals
38. Recommended prostate-specific testing intervals for the detection of curable prostate cancer
39. When is PSA testing no longer necessary?